Phrixus Pharmaceuticals
  • European Access Program
    for Carmeseal-MD™
  • Our People
    • Management
    • Board of Directors
    • Scientific and Medical Advisory Board
  • Product Background
    • Preclinical Efficacy Results
    • Preclinical Safety Results
    • Previous Human Experience
  • Indications
  • Contact

Contact

Phrixus Pharmaceuticals, Inc.
1600 Huron Parkway
Building 520, 2nd Floor
Ann Arbor, MI 48109

1 (734) 358 (dash) 9015
thomas (dot) collet (at) phrixuspharmaceuticals (dot) com

Share

Latest News

  • Phrixus Pharmaceuticals announces Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy
  • Phrixus Pharmaceuticals announces the first patient with Duchenne muscular dystrophy (DMD) to meet the 15-month mark on Carmeseal-MD™ (Poloxamer 188 NF)
  • FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)
  • Carmeseal-MD™, the first disease-modifying agent for skeletal limb muscle, diaphragm and heart
  • Independent study confirms hypothesized mechanism of action for Carmeseal-MD™ (P-188 NF) as membrane sealant on dystrophic cells
  • Carmeseal-MD™ (P-188 NF) improves respiratory and cardiac dysfunction in dystrophic mice after subcutaneous administration
  • Phrixus Pharmaceuticals Receives Services from NIH
  • Phrixus Pharmaceuticals Announces European Access Program
  • Phrixus Pharmaceuticals Announces SMARTT/NHLBI Award
  • Phrixus Pharmaceuticals Announces Funding by DuchenneDashboard
  • Phrixus Pharmaceuticals Reports Positive Preclinical Results
  • Phrixus Pharmaceuticals Announces $623,000 in NIH Funding
  • Phrixus Pharmaceuticals Announces $890,000 in NIH Funding
  • Facebook
  • Twitter
  • RSS